3 results about "Cytochrome c" patented technology

The present disclosure is directed to compositions comprising mitochondrial optogenetics-based gene therapies and their methods of use. In some embodiments, a composition described herein comprises an expression vector comprising a first nucleic acid sequence encoding a channelrhodopsin fusion protein and a second nucleic acid sequence encoding a luciferase protein. In some cases, the first nucleic acid sequence and the second nucleic acid sequence are operably linked to an expression control sequence. In some instances, the channelrhodopsin fusion protein comprises a channelrhodopsin protein linked to an inner mitochondrial membrane-mitochondrial localization signal (IMM-MLS). In some implementations, when the expression vector is expressed, the luciferase protein is localized to the cytosol. In some cases, the IMM-MLS comprises a leading sequence from a mitochondrial inner membrane protein selected from ABCB10, ABCB140, Cytochrome C, and renal outer medullary potassium channel (ROMK).

This invention discloses a vitamin C smart delivery nanocomponent based on biomimetic imprinting technology and its anti-tumor application. The core of the nanocomponent is a SiO2 nanoparticle containing cytochrome C, and the surface is directionally imprinted with a vitamin C-specific imprinted cavity using ascorbyl glucoside (AA2G), a stable derivative of vitamin C, as a molecular imprinting template. The preparation steps include: SiO2 nanoparticles containing cytochrome C. 2 The synthesis, amino-functionalization, boric acid-functionalization, template immobilization, directional imprinting, secondary amino-functionalization, template removal, and DMMA modification of NPs-CC led to the construction of the nano-component vMIPDcc containing cytochrome C in its core and having a vitamin C-specific imprinted cavity on its surface. This nanocomponent exhibits high selectivity (IF=8.4) and reliable recognition ability for vitamin C. vMIPDcc achieved an in vivo inhibition rate of 60.2% against colon cancer, providing new ideas and options for the development of anti-colon cancer drugs.